InSphero AG products

Test efficacy of anti-NASH drugs in an advanced 3D human liver disease model. The InSphero 3D InSight™ Human Liver NASH Model consists of an advanced microtissue co-culture of healthy primary human liver cells combined with specially formulated media and cocktails that induce the progression of NAFLD and NASH from steatosis to liver inflammation and fibrosis.  Ideal for investigating mechanisms of non-alcoholic steatohepatitis (NASH) induction, in vitro screening of anti-NASH drug efficacy, and safety assessment of drug candidates in a relevant disease background, this powerful model includes all the critical liver cells and inducers needed to recapitulate the progression of human fatty liver disease.

Fail early, fail fast! Assess Risk of Liver Injury Due to Compound Exposure with 3D InSight. 3D InSight Human Liver Microtissues are pharma-validated, preclinical co-culture liver models for toxicology testing that have been shown to achieve 2X higher sensitivity for DILI prediction compared to traditional 2D PHH.  These advanced 3D liver models, which combine multi-donor diversity with structural and functional robustness, are ideal for drug safety and efficacy testing as well as the study of healthy and diseased liver function. Upon request, microtissues from individual donor hepatocyte lots are also available.

3D InSight™ Human Islet Microtissues are a standardized alternative to primary human pancreatic islets for reproducible, reliable, and more efficient research. Expand your GSIS assay window and improve sensitivity to insulin secretagogues with a long-lived, robust model persisting more than 28 days in culture. Eliminate islet pooling and data normalization with islet microtissues homogeneous in size and cellular composition. Increase efficiency 6-fold by eliminating the need to hand pick islets with microtissues available bimonthly and delivered assay-ready in a non-adherent, 96-well plate.

A standardized in vitro rat islet model for translational diabetes studies and toxicity testing. InSphero 3D InSight™ Rat Islet Microtissues are currently in the final stages of product development and quality control testing. If you are interested in beta testing this product to help us further characterize the model and develop useful endpoints.

An in vitro PDX model with in vivo-like heterogeneity. 3D InSight™ Tumor Microtissues from Patient-Derived Xenografts (PDX) are custom assay-ready 3D in vitro tumor models engineered to reflect complex tumor biology without the use of artificial matrices. Ideal for early stage cancer drug efficacy testing and screening appliciations, these advanced cancer models help bridge the gap between preclinical animal studies and translation of outcome into clinical applications, and enable oncologists to quickly identify the most promising mouse PDX models for subsequent in vivo testing.

When you’re ready, we deliver. InSphero assay-ready spheroid microtissues are engineered and certified for use in critical drug development applications, and validated to ensure uniform size, robust functionality, and reproducible results. We develop 3D InSight™ Microtissues using the most advanced 3D cell culture technologies available to produce highly predictive, fully QC’d organotypic in vitro models ready to use in pharma drug discovery, efficacy and safety. These microtissues form the foundation of our 3D InSight™ platforms for drug discovery and safety, which we rely on in all our research collaborations and services.  Many of our liver and islet models are also available as assay-ready microtissues, shipped live and ready to use to labs throughout Europe and North America.